Last reviewed · How we verify
MSB11455
At a glance
| Generic name | MSB11455 |
|---|---|
| Sponsor | Fresenius Kabi SwissBioSim GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects (PHASE1)
- Safety and Immunogenicity of MSB11455 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSB11455 CI brief — competitive landscape report
- MSB11455 updates RSS · CI watch RSS
- Fresenius Kabi SwissBioSim GmbH portfolio CI